Market Spotlight: Venous Thromboembolism (VTE)


Report
36 Pages
February 2021
Region: Global
Citeline
ID: 5118950

This Market Spotlight report covers the Venous Thromboembolism market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2018, there were approximately 2.3 million incident cases of deep vein thrombosis (DVT) and 1.2 million incident cases of pulmonary embolism (PE) worldwide, and forecasts that these numbers will increase to 2.6 million incident cases of DVT and 1.3 million incident cases of PE by 2027.
Approved drugs in the venous thromboembolism (VTE) space focus on a wide variety of targets. These drugs are commonly administered via the subcutaneous route, with some products being available in oral and intravenous formulations.
The majority of industry-sponsored drugs in active clinical development for VTE are in Phase II. Therapies in active clinical development for VTE focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral and subcutaneous formulations.
The only high-impact upcoming event in the VTE space is an expected supplemental CHMP opinion for Xarelto. The overall likelihood of approval of a Phase I VTE asset is 20.2%, and the average probability a drug advances from Phase III is 70%. Drugs, on average, take 10.9 years from Phase I to approval, compared to 9.3 years in the overall hematology space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for VTE have been in the late phases of development, with 72% of trials in Phase III–IV, and 28% in Phase I–II.
The US has a slight lead in the number of VTE clinical trials globally, while Germany leads the major European markets. Clinical trial activity in the VTE space is dominated by completed trials. Bayer has the highest number of completed clinical trials for VTE, with 38 trials.
Bayer leads the industry sponsors with the highest overall number of clinical trials for VTE.

OVERVIEWKEY TAKEAWAYS

DISEASE BACKGROUND

Disease definition
Symptoms
Risk factors
Diagnosis
Patient segmentation

TREATMENT

Anticoagulants
Thrombolytic therapy
Inferior vena cava filter
Thrombectomy/embolectomy

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS

KEY REGULATORY EVENTS

Japan: Bayer’s Xarelto Receives Approval For Additional Indications Of Venous Thromboembolism
Accord Gets First EU-Wide Nod For Xarelto Rival

PROBABILITY OF SUCCESSREVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status
Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

LIST OF FIGURES

Figure 1: Trends in incident cases of DVT, 2018–27
Figure 2: Trends in incident cases of PE, 2018–27
Figure 3: Overview of pipeline drugs for VTE in the US
Figure 4: Pipeline drugs for VTE, by company
Figure 5: Pipeline drugs for VTE, by drug type
Figure 6: Pipeline drugs for VTE, by classification
Figure 7: Probability of success in the VTE pipeline
Figure 8: Clinical trials in VTE
Figure 9: Top 10 drugs for clinical trials in VTE
Figure 10: Top 10 companies for clinical trials in VTE
Figure 11: Trial locations in VTE
Figure 12: VTE trials status
Figure 13: VTE trials sponsors, by phase

LIST OF TABLES

Table 1: Incident cases of DVT, 2018–27
Table 2: Incident cases of PE, 2018–27
Table 3: Marketed drugs for VTE
Table 4: Pipeline drugs for VTE in the US
Table 5: Historical global sales, by drug ($m), 2015–19
Table 6: Forecasted global sales, by drug ($m), 2021–25

Table of Contents

Related Topics

Related Reports

Venous Thromboembolism Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2032

Venous Thromboembolism - Pipeline Insight, 2024

Venous Thromboembolism (VTE) Epidemiology Analysis and Forecast to 2032

Global Venous Thromboembolism Therapeutic Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Venous Thromboembolism Prophylaxis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F